Product Pathways - Tyrosine Kinase / Adaptors
ROS1 (D4D6®) Rabbit mAb (PE Conjugate) #35550
|35550S||100 µl ( 50 tests )||￥4,060.00||现货查询 购买询价 防伪查询|
|35550||carrier free & custom formulation / quantity||email request|
Species cross-reactivity is determined by western blot.
Applications Key: F=Flow Cytometry,
Specificity / Sensitivity
ROS1 (D4D6®) Rabbit mAb (PE Conjugate) recognizes endogenous levels of total ROS1 protein. The unconjugated antibody does not cross-react with other related proteins when analyzed by western blot. Please note that staining may be observed in ROS1 rearranged lung carcinomas, macrophages/giant cells, reactive type II pneumocyte hyperplasia, and the epithelium in areas of bronchiolar metaplasia. Staining of unknown specificity has been observed in cholangiocarcinoma, hepatocellular carcinoma, and kidney tissues.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a protein corresponding to residues in the carboxy terminal domain of the human ROS1 protein.
This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. This antibody is expected to exhibit the same species cross-reactivity as the unconjugated ROS1 (D4D6®) Rabbit mAb #3287.
ROS1, an orphan receptor tyrosine kinase of the insulin receptor family, was initially identified as a homolog of v-ros from the UR2 sarcoma virus (1). ROS1 consists of a large extracellular domain that is composed of six fibronectin repeats, a transmembrane domain, and an intracellular kinase domain. While the function of ROS1 is undefined, it has been shown to play an important role in differentiation of epididymal epithelium (2). The first oncogenic fusion of ROS1, FIG-ROS1, was initially identified by research studies in glioblastoma (3), and subsequent studies have found this fusion in cholangiocarcinoma (4), ovarian cancer (5) and non-small cell lung cancer (NSCLC) (6). Investigators have found additional oncogenic ROS1 fusion proteins in NSCLC (at a frequency of ~1.6%), where the ROS1 kinase domain is fused to the amino-terminal region of a number of different proteins, including CD74 and SLC34A2 (6-8). ROS1 fusion proteins activate the SHP-2 phosphatase, PI3K/Akt/mTOR, Erk, and Stat3 pathways (3,4,9).
- Matsushime, H. et al. (1986) Mol Cell Biol 6, 3000-4.
- Yeung, C.H. et al. (1999) Biol Reprod 61, 1062-9.
- Charest, A. et al. (2003) Genes Chromosomes Cancer 37, 58-71.
- Gu, T.L. et al. (2011) PLoS One 6, e15640.
- Birch, A.H. et al. (2011) PLoS One 6, e28250.
- Rimkunas, V.M. et al. (2012) Clin Cancer Res 18, 4449-57.
- Rikova, K. et al. (2007) Cell 131, 1190-203.
- Stumpfova, M. and Jänne, P.A. (2012) Clin Cancer Res 18, 4222-4.
- Jun, H.J. et al. (2012) Cancer Res 72, 3764-74.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
D4D6 is a registered trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
用户评论 --- 共 0 条